Q1 2026 Management View CEO Thomas McCourt said 2026 priorities remain “maximizing LINZESS, advancing apraglutide and delivering sustained profits and cash flow,” and highlighted Q1 execution across ...
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported a strong start to 2026 and reiterated its full-year outlook, pointing to ...
Ironwood Pharmaceuticals reaffirmed its 2026 financial guidance, including $1.125B–$1.175B in U.S. LINZESS sales, as it approaches a May 24 FDA decision on a pediatric indication. Q1 saw 97% year-over ...
U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year – ...
Linzess comes as an oral capsule. It belongs to a class of drugs called guanylate cyclase-C agonists. At this time, Linzess is only available in a brand-name form. There’s currently no generic version ...
Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...
Inform your doctor of all medications, supplements, and health conditions that apply to you before taking Linzess to prevent possible interactions. Linzess may interact with antidiarrheal and ...
Linzess comes as a capsule that you swallow. Keep reading for details on Linzess and cost and how to save money on prescriptions. »LEARN MORE:For more details about this medication, check out this ...
Linzess may interact with anticholinergic drugs, such as oxybutynin (Ditropan XL), and antidiarrheal drugs, such as loperamide (Imodium). Taking these drugs with Linzess can make Linzess less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results